8/20/2014 10:18:08 AM
PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE: LCI) today commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology (JACC), which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF (The Retrospective Evaluation and Assessment of Therapies in AF) study from the U.S. Department of Veterans Affairs (VA) healthcare system.
“Digoxin has long been an important treatment option for cardiovascular disease,” said Arthur Bedrosian, president and chief executive officer of Lannett. “As with most medications, we believe medical care providers will continue to prescribe Digoxin unless a more effective alternative medication is available.”
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by